Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NMTC vs NPCE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NPCE Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

NPCE Overall Winner 6-Pillar Tally: NMTC 1 – 4 NPCE (1 Tie) Matrix Metrics: NMTC 2 – 8 NPCE

As of Nov 20, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas NPCE carries 54.4/100 (HOLD) at $7.95 (91.7x Forward P/E, -9.6% operating margin).

  • Growth vs. Quality Trade-Off: NPCE earns the overall head-to-head edge with a stronger Unified Composite Score (54.4/100 HOLD vs. NMTC 45.5/100 HOLD) and 1.17β · 135% Vol risk profile, whereas NMTC leads top-line expansion (+16.3% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMTC vs NPCE
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03
NPCE NASDAQ Head-to-Head Winner
Neuropace, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$7.95
-2.33% 1D
Market Cap $280.4M
TTM Revenue $107M
Forward P/E 91.7x
Beta / 30D Vol 1.17β · 135% Vol
Unified Composite Score
54.4 / 100 HOLD
Tech 55.0 Fund 61.0 Flow 67.0 Mom 73.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 26
RSI-14: 25.6 · SMA20: $11.29 · SMA50: $12.57

6-Pillar Scorecard Institutional Category Breakdown (NMTC 1 – 4 NPCE)

Columns: Metric · NMTC · NPCE
1. Valuation Multiples NPCE
Forward P/E N/M 91.7x
Trailing P/E N/M 91.7x
PEG Ratio N/M N/M
EV / Revenue 0.3x 3.2x
2. Growth & Scale NPCE
Revenue Growth (YoY) +16.3% -1.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $12M $107M
Market Cap $6.1M $280.4M
3. Profitability & Quality NPCE
Gross Margin 23.0% 77.8%
Operating Margin -63.4% -9.6%
Net Profit Margin -59.7% -17.7%
Return on Equity (ROE) -124.7% -97.0%
4. Balance Sheet & Cash Flow NPCE
Cash Generation (TTM) -$7.6M -$12M
Cash Flow Margin -60.7% -11.6%
Net Cash / Leverage $2.6M Net Cash $59M Net Debt (6.05x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NMTC
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 59.9% (10th %ile)
Put/Call OI Skew N/A 0.38x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMTC (2) vs NPCE (8)
Institutional Metric NMTC NPCE Criterion Row Edge
Market Capitalization
Scale
$6.1M $280.4M Larger Scale NPCE
Trailing P/E Ratio
Valuation
N/M 91.7x Lower Multiple NPCE
Forward P/E Ratio
Valuation
N/M 91.7x Lower Multiple NPCE
Revenue Growth (YoY)
Growth
+16.3% -1.1% Higher Growth NMTC
Operating Margin (TTM)
Profitability
-63.4% -9.6% Higher Margin NPCE
Net Profit Margin
Profitability
-59.7% -17.7% Higher Margin NPCE
Return on Equity (ROE)
Capital Efficiency
-124.7% -97.0% Higher ROE NPCE
52-Week Range Position
Momentum
2% ($1–$5) 18% ($5–$20) Stronger Trend NPCE
Beta / 30D Volatility
Risk Regime
1.55β · 105% Vol 1.17β · 135% Vol Lower Realized Risk NMTC
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 54.4 / 100 (HOLD) Higher Composite NPCE
Trailing 12M Revenue (USD)
Operating Scale
$12M $107M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.0% 77.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($2.6M Net Cash) -$12M ($59M Net Debt (6.05x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NMTC +6.04 pp
NMTC: -33.46% · NPCE: -39.5%
3M Horizon NPCE +26.36 pp
NMTC: -69.53% · NPCE: -43.17%
6M Horizon NPCE +29.32 pp
NMTC: -82.33% · NPCE: -53.01%
1Y Horizon NMTC +47.11 pp
NMTC: +3.49% · NPCE: -43.62%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NMTC Revenue NPCE Revenue NMTC Op. Margin NPCE Op. Margin Margin Leader
FY2013 $0M N/A -2009.0% N/A NMTC
FY2014 $0M N/A -4646.1% N/A NMTC
FY2020 N/A $40M N/A -31.7% NPCE
FY2021 $0M $50M -5735.9% -52.5% NPCE
FY2022 $0M $50M -5860.2% -89.6% NPCE
FY2023 $0M $70M -612.3% -41.5% NPCE
FY2024 $0M $80M -344.3% -27.1% NPCE
FY2025 $10M $100M -46.5% -16.3% NPCE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NPCE BREAKDOWN
137d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 10th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NPCE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NPCE Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $280.4M market capitalization and -9.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NMTC vs NPCE Key Questions & Quantitative Answers

As of Nov 20, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas NPCE carries 54.4/100 (HOLD) at $7.95 (91.7x Forward P/E, -9.6% operating margin). Growth vs. Quality Trade-Off: NPCE earns the overall head-to-head edge with a stronger Unified Composite Score (54.4/100 HOLD vs. NMTC 45.5/100 HOLD) and 1.17β · 135% Vol risk profile, whereas NMTC leads top-line expansion (+16.3% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NPCE leads the Growth & Scale pillar: NMTC posts +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin), compared with NPCE at -1.1% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (77.8% gross margin, -9.6% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), NMTC cumulative revenue shifted N/A while NPCE shifted +150.0%. In operating R&D and SG&A reinvestment, NMTC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NPCE.

NPCE screens cheaper on headline valuation multiples. NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin), whereas NPCE trades at 91.7x Forward P/E, 91.7x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-11.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMTC (-124.7% ROE) versus NPCE (-97.0% ROE) capital efficiency.

In options market volatility and institutional positioning, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk). By comparison, NPCE carries 59.9% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.17β · 135% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.